This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
This article is part of WikiProject AIDS, an attempt to build a comprehensive, detailed, and accessible guide to AIDS, HIV, and related topics on Wikipedia. If you would like to participate in the project, you can choose to edit this article, or visit the project page for more information.AIDSWikipedia:WikiProject AIDSTemplate:WikiProject AIDSAIDS articles
Need to merge in details on the coformulations page. References for several statements in this text need to be found/information clarified. The information there is currently:
Kaletra® = lopinavir (for its HIV protease enzyme inhibition) with ritonavir included to boost serum levels of lopinavir through inhibition of CYP3A4, a liver enzyme that metabolizes many other substances. The FDA approved it September 15, 2000, making it the seventeenth approved antiretroviral drug. It is the first multi-drug capsule that contains a drug not available individually. It has been demonstrated to be extremely potent and is often used in 'salvage' therapy for patients with some level of drug resistance. Some studies have suggested Kaletra is potent enough to be used as monotherapy and is also suitable for once-daily dosing, although neither is currently recommended. Marketed by Abbott Laboratories, its patent will expire in the United States on 2016-06-26.
